Can Psychedelics Treat Alcoholism? New Psilocybin & DMT Studies Say YES!

Can Psychedelics Treat Alcoholism? New Psilocybin & DMT Studies Say YES Wakeful Travel Kickstarter: https://www.kickstarter.com/projects/920110985/wakeful-travel-journals-support-your-transformation?ref=f1y202 In today's episode, we dive into two pre-clinical studies testing psychedelics' effectiveness in treating alcohol-related illnesses. In the first, researchers tested psilocybin (magic mushrooms) on mice who got addicted to alcohol. They found that the psilocybin helped repair a part of their brain that alcohol abuse damaged. This helped the mice make less neurotic decisions, and helped them abstain from alcohol. This is promising, and if it can be repeated in humans, it would be a huge step forward in treating alcoholism. The second study looked at the Ayahuasca brew, which has as its main psychoactive ingredient DMT. In this study, the researchers found that the mice who took the ayahuasca were less likely to seek out more alcohol. Again, if this can be replicated in humans, it would show the powerful benefits of psychedelic medicines to treat alcoholism. Psychedelics and mental health have long been a topic of research, and we are finally getting data that psychedelics like psilocybin and DMT may be effective in treating a variety of mental health conditions, such as alcoholism. Links: Psilocybin Study https://www.science.org/doi/10.1126/sciadv.abh2399#F5 Psilocybin article https://www.inverse.com/mind-body/psilocybin-repairs-alcohol-brain-damage Ayahuasca study: https://pubmed.ncbi.nlm.nih.gov/34822961/ Enjoy the episode! Follow us on social media! Instagram: @thepsychedelicinvestor Facebook: @thepsychedelicinvestor James’ Twitter: @Psy_Invest Maria’s Twitter (Producer & Editor): @Psy_Holy Want to collaborate? Send us an email at: thepsychedelicinvestor@gmail.com Music from: www.bensound.com Video editing: @themyaholy DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments. All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change. #Psilocybin #DMT #Psychedelics

Wesana Health’s Dr. ABID NAZEER – The Parallels Between Brain Injury & Addiction (WESA)

Wesana Health's Dr. ABID NAZEER - The Parallels Between Brain Injury & Addiction (WESA) Dr. Nazeer is the Founder and President of APS Ketamine/Advanced Psychiatric Solutions, which was recently acquired by Wesana Health (OTC: WSNAF, CSE:…
Psychedelic Business Spotlight: November 26

Psychedelic Business Spotlight: November 26

,
This week in psychedelic business news: Compass Pathways files another patent; Seelos Therapeutics raises big money; Cybin makes psychedelic therapy more accessible in NYC.

Numinus Wellness CEO Discusses MAPS Partnership & How Psychedelics Will Change Society

In this episode James, from The Psychedelic Investor, sits down with Numinus Wellness’ (OTC: NUMIF, TSX.V: NUMI) CEO Payton Nyquvest for the Psychedelic Spotlight Podcast. Numinus is a Psychedelic Medicines company focused on scaling up…

The Psychedelic Sector has Reached “Escape Velocity” | An interview with Cybin’s CEO (CYBN)

In this episode, James, The Psychedelic Investor, sits down with Doug Drysdale, CEO of Cybin (NYSE: CYBN) for the Psychedelic Spotlight podcast. In the interview, the two discuss Cybin’s psychedelic medicines portfolio, and where the psychedelic industry is going in the next few years. Can psychedelics heal mental health? The main topic was attempting to answer the question: can psilocybin heal mental health conditions like depression? Doug Drysdale spoke on the positive results we have seen in psilocybin for depression clinical trials, such as the Compass Pathways’ psilocybin (comp 360) for treatment-resistant depression phase 2b trial. Despite the apparent benefits of psilocybin, though, Doug Drysdale and Cybin argued that there were 3 core problems with using psilocybin in a therapy setting: the long duration of effect; the onset action period; and the variability of effect. Cybin has developed a new version of psilocybin, called CYB-003. CYB-003 has a shorter duration, reaches peak effect quicker, and has less variability in effect between individuals. Plus, it keeps all of the therapeutic benefits of psilocybin and its subjective effects. It is important to note that Cybin’s Cyb-003, their next-generation psilocybin, has only been tested in animals up until this point. They intend to start human clinical trials next year. James and Doug of Cybin also discussed the other Cybin projects, such as CYB-004, and their development strategy. They also discussed government policy, and whether the psychedelics sector has reaches escape velocity. In all, this psychedelic medicines conversation was fascinating and showed Cybin’s dedication towards improving mental health conditions, which are abysmal in the United States right now. Enjoy the episode! Follow us on social media! Instagram: @thepsychedelicinvestor Facebook: @thepsychedelicinvestor James’ Twitter: @Psy_Invest Maria’s Twitter (Producer & Editor): @Psy_Holy Want to collaborate? Send us an email at: thepsychedelicinvestor@gmail.com Music from: www.bensound.com Video editing: @themyaholy DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments. All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change. #Cybin #Psilocybin #Psychedelics

MindCure CEO Kelsey Ramsden – The Psychedelic Space Is Unlike Any Other Drug Development Sector

In this interview with Kelsey Ramsden, CEO on MindCure Health (CSE:MCUR) (OTC: MCURF), David Flores, CEO of Global Trac Solutions and Swati Sharma, Media Director of Psychedelic Spotlight, discuss a few interesting topics that surround the…
PharmaTher Believes Ketamine Could Treat This Rare Neurological ConditionShutterstock.com

PharmaTher Believes Ketamine Could Treat This Rare Neurological Condition

,
The company is also exploring if ketamine can treat other neurological conditions, including Parkinson’s Disease, ALS, and CRPS.
Sena Maria On The Benefits of Microdosing

Sena Maria On The Benefits of Microdosing

,
In this episode, Sena Maria gives us an overview of her Microdosing Activation program and explains some of the benefits of microdosing.
Doug Drysdale Cybin

Doug Drysdale On How CYB-003 Is Better Than Psilocybin

In this episode, James Hallifax from the Psychedelic Investor, interviews Doug Drysdale, CEO of Cybin (NYSE: CYBN). In this fantastic discussion, Doug and James discuss the potential for psilocybin (magic mushrooms) to treat depression and other mental health issues.
How the COVID Pandemic Inspired Wakeful Travel's Psychedelic Integration Journals

How the COVID Pandemic Inspired Wakeful Travel’s Psychedelic Integration Journals

A travel journal company pivots from external trips to those unfolding in the mind, and the psychedelic community is embracing the one-of-a-kind integration workbook with open arms.